Healthcare, Regulatory and Reimbursement Landscape - Canada

Introduction

Abstract

Healthcare, Regulatory and Reimbursement Landscape - Canada

Summary

GlobalData, the industry analysis specialist, has released its new report, "Healthcare, Regulatory and Reimbursement Landscape - Canada". The report is an essential source of information and an analysis on the healthcare, regulatory, and reimbursement landscape of Canada. The report identifies the key trends in the Canadian healthcare market, and also provides insights on the demographic, regulatory, and reimbursement landscape, as well as the healthcare infrastructure. Most importantly, the report provides valuable insights on the trends and segmentation of the pharmaceutical and medical devices markets. This report was developed using data and information sourced from proprietary databases, secondary research, and in-house analysis by GlobalData's team of industry experts.

Canada's population was approximately 34.4 million in 2011, and is growing largely as a result of immigration. The natural growth rate of the population is projected to be low due to the balance between the mortality and birth rates. The increasing elderly population, however, is a matter of concern for policy planners.

The pharmaceutical market in Canada was valued at about $21.5 billion in 2010 and is expected to reach approximately $45.9 billion by 2020, at a projected 9.9% CAGR. The medical device market was valued at approximately $7.7 billion in 2011 and is expected to reach approximately $12.2 billion by 2020, at a projected 5.2% CAGR.

The positive trend in the Canadian healthcare market can be attributed primarily to -

• Increasing elderly population
• Universal healthcare coverage
• High degree of access to healthcare facilities
• Government initiatives for the prevention and management of chronic diseases
• Strong, efficient, and transparent guidelines that simplify the regulatory process

Scope

The report provides information on the healthcare, regulatory, and reimbursement landscape of Canada. The scope includes -

• Overview of the pharmaceutical and medical devices market of Canada including the market size, market segmentation, and key drivers and barriers for the market.
• Profile and SWOT analysis of the major players in the pharmaceutical and medical devices markets. Key players covered for the pharmaceutical market are Pfizer, GlaxoSmithKline, Sanofi, AstraZeneca, and Apotex. Key players covered for the medical devices market are Medtronic, Siemens Healthcare, Essilor International, GlaxoSmithKline, and Zimmer Holdings.
• Insightful review on the reimbursement and regulatory landscape. Analysis includes details of the healthcare reimbursement process, regulatory agencies and market authorization process for new drug and medical devices for Canada.
• A detailed analysis of the political and economic environment of Canada, including key economic indicators, demographics, healthcare infrastructure and healthcare expenditures.
• An overview of the opportunities and challenges for growth that exist in the Canadian healthcare market.

Reasons to buy

This report provides comprehensive coverage of both the pharmaceutical and the medical devices markets in Canada. It will enhance your decision-making capability by allowing you to -

• Develop business strategies by understanding the trends shaping and driving the Canadian healthcare market
• Drive revenues by understanding the key trends, reimbursement and regulatory policies, pharmaceutical and medical devices market segments, and companies likely to impact the market in future
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments, and strategic partnerships
• Identify, understand, and capitalize on the opportunities and challenges in the healthcare market of Canada

Table of Contents

TOC

1 Table of Contents

1 Table of Contents 5

• 1.1 List of Tables 7
• 1.2 List of Figures 9

2 Introduction 11

• 2.1 GlobalData Report Guidance 11

3 Overview of the Pharmaceutical and Medical Devices Market 12

• 3.1 Pharmaceutical Market 12
• 3.1.1 Market Overview 12
• 3.1.2 Supply Channel 15
• 3.1.3 Pricing 15
• 3.1.4 Market Segments 17
• 3.1.5 Major Disease Areas 21
• 3.1.6 Major Players 23
• 3.2 Medical Device Market 50
• 3.2.1 Market Overview 50
• 3.2.2 Overview of Top Five Segments 52
• 3.2.3 Major Players 63
• 3.3 Market Drivers and Barriers 82
• 3.3.1 Drivers 82
• 3.3.2 Barriers 82

4 Market Access 84

• 4.1 Overview of the Healthcare System 84
• 4.2 Reimbursement and Payer Landscape 85
• 4.2.1 Drug Reimbursement Process 85
• 4.2.2 Overview of Insurance Providers 89
• 4.2.3 Patient Share in Healthcare Spending 91
• 4.2.4 Patented Drug Price Trend 92
• 4.2.5 Pricing Policies 92
• 4.3 Regulatory Landscape 93
• 4.3.1 Overview of Regulatory Agencies 93
• 4.3.2 New Drug Approval Process 94
• 4.3.3 New Medical Device Approval Process 98
• 4.3.4 Licensing Process for Pharmaceutical Manufacturing 101
• 4.3.5 Licensing Process for Pharmaceutical Exports and Imports 102
• 4.3.6 Patent Application Process 103
• 4.3.7 Clinical Trial Regulations 105
• 4.3.8 Pharmaceutical Advertising Regulations 107
• 4.3.9 Pharmacy Regulations 107
• 4.3.10 Labeling and Packaging Regulations 108

5 Country Analysis 110

• 5.1 Political Environment 110
• 5.1.1 Political Structure 110
• 5.1.2 Analysis of Current Political Environment 111
• 5.1.3 Healthcare Policy Initiatives 111
• 5.2 Economic Landscape 112
• 5.3 Economic Indicators 113
• 5.3.1 Gross Domestic Product 113
• 5.3.2 Gross National Income 117
• 5.3.3 Inflation 118
• 5.3.4 Currency Exchange Rate 122
• 5.3.5 Foreign Direct Investment 123
• 5.3.6 Foreign Exchange Reserves 124
• 5.3.7 Trade Balance 125
• 5.3.8 General Government Structural Balance 127
• 5.3.9 General Government Net Debt 128
• 5.3.10 Major Industries 130
• 5.4 Demographics 132
• 5.4.1 Population 132
• 5.4.2 Education and Literacy 149
• 5.4.3 Employment 151
• 5.4.4 Disease Burden 152
• 5.5 Healthcare Infrastructure 154
• 5.5.1 Healthcare Facilities 154
• 5.5.2 Healthcare Parameters 163
• 5.5.3 Environmental Health 166
• 5.5.4 Healthcare Personnel 168
• 5.6 Healthcare Expenditures 169
• 5.6.1 Overview 169
• 5.6.2 Major Components of Healthcare Spending 170
• 5.6.3 Share of Public and Private Sectors 171
• 5.6.4 Pharmaceutical R&D Expenditures 173
• 5.7 Trade Associations 174
• 5.7.1 Canadian Pharmacists Association (CPhA) 174
• 5.7.2 Canadian Association of Professional Regulatory Affairs (CAPRA) 174
• 5.7.3 Canada Society for Pharmaceutical Sciences (CSPS) 174
• 5.7.4 Canadian Society of Hospital Pharmacists (CSHP) 174
• 5.7.5 Canadian Generic Pharmaceutical Association (CGPA) 174
• 5.8 Trade Fairs 175

6 Opportunities and Challenges 176

• 6.1 Opportunities 176
• 6.2 Challenges 176

7 Appendix 178

• 7.1 Abbreviations 178
• 7.2 Bibliography 181
• 7.3 Methodology 186
• 7.3.1 Coverage 186
• 7.3.2 Secondary Research 186
• 7.3.3 Forecasting 186
• 7.3.4 Primary Research 187
• 7.3.5 Expert Panel Validation 187
• 7.4 Contact Us 187
• 7.5 Disclaimer 187

List of Tables

1.1 List of Tables

• Table 1: Pharmaceutical Market ($bn), Canada, 2005-2010 13
• Table 2: Pharmaceutical Market ($bn), Canada, Forecast, 2011-2020 14
• Table 3: Classification of Drugs Canada 15
• Table 4: Wholesale Mark-Up Charge, Canada, 2012 16
• Table 5: Generic Pharmaceuticals, Canada, Revenue ($bn), 2005-2010 17
• Table 6: Biologics Pharmaceuticals, Canada, Revenue ($bn), 2005-2010 18
• Table 7: Biologics Pharmaceuticals, Canada, Revenue ($bn), 2011-2020 19
• Table 8: OTC Drugs Market, Canada, Revenue ($bn), 2005-2010 20
• Table 9: Major Disease Areas for Patented Drugs, Canada, Market Share (%), 2010 21
• Table 10: Major Products, Pfizer, Global, Revenue ($m), 2011 24
• Table 11: Late-Stage Pipeline, Pfizer, 2012 24
• Table 12: Major Products, GlaxoSmithKline, Global, Revenue ($m), 2011 29
• Table 13: Late-Stage Pipeline, GlaxoSmithKline, 2012 30
• Table 14: Major Products, Sanofi, Global, Revenue ($m), 2011 35
• Table 15: Late-Stage Pipeline, Sanofi, 2012 35
• Table 16: Major Products, AstraZeneca, Global, Revenue ($m), 2011 39
• Table 17: Late-Stage Pipeline, AstraZeneca, 2012 40
• Table 18: Major Products, Apotex, Global, 2012 45
• Table 19: Potential Generic Products, Apotex, 2012 47
• Table 20: Medical Device Market ($bn), Canada, 2006-2011 50
• Table 21: Medical Device Market ($bn), Canada, Forecast, 2012-2020 51
• Table 22: Medical Device Market, Canada, Segments, Revenue ($m), 2011 52
• Table 23: Ophthalmic Devices Market ($m), Canada, 2006-2011 53
• Table 24: Sales Trends for Major Players*, Ophthalmic Devices, Canada, 2010 54
• Table 25: Orthopedic Devices Market ($m), Canada, 2006-2011 55
• Table 26: Sales Trends for Major Players*, Orthopedic Devices, Canada, 2010 56
• Table 27: Cardiovascular Devices Market ($m), Canada, 2006-2011 57
• Table 28: Sales Trends for Major Players*, Cardiovascular Devices, Canada, 2010 58
• Table 29: In Vitro Diagnostics Market ($m), Canada, 2006-2011 59
• Table 30: Sales Trends for Major Players*, In Vitro Diagnostics, Canada, 2010 60
• Table 31: Drug Delivery Devices Market ($m), Canada, 2006-2011 61
• Table 32: Sales Trends for Major Players*, Drug Delivery Devices, Canada, 2010 62
• Table 33: Major Medical Device Companies, Canada, Revenue ($m), 2010 63
• Table 34: Major Products, Medtronic, Global, Revenue ($m), 2011 64
• Table 35: Major Products, Siemens, Global, Revenue ($m), 2010 68
• Table 36: Major Segments, Essilor International, Global, Revenue ($m), 2010 71
• Table 37: Major Products, GlaxoSmithKline, Global, Revenue ($m), 2010 74
• Table 38: Levels of Therapeutic Improvement, 2012 87
• Table 39: PharmaCare Plans, 2011 89
• Table 40: Healthcare Spending, Canada, Patient's Share (%), 2005-2010 91
• Table 41: Change in Average Price of Patented Drugs (%), Canada, 2005-2010 92
• Table 42: Target Review Times for New Drug Submissions, Canada, 2012 95
• Table 43: Therapeutic Product Submissions to HPFB, Canada, 2010 97
• Table 44: New Drug Submission Review Decisions, Canada, 2010 97
• Table 45: Fees for Review of Drug Submissions and Applications, 2012 98
• Table 46: Classes of Medical Devices, 2006 98
• Table 47: Medical Device Licensing Fees (CAD$), Canada, 2012 101
• Table 48: Medical Device Licensing, Canada, Time Period, 2012 101
• Table 49: Target Performance Standings for Drug Submission Review, Canada, 2011 107
• Table 50: GDP Per Capita ($), Canada, 2005-2010 114
• Table 51: GDP Per Capita ($), Canada, Forecast, 2011-2020 114
• Table 52: GDP, Canada, Annual Growth (%), 2005-2010 115
• Table 53: GDP, Canada, Annual Growth (%), Forecast, 2011-2020 116
• Table 54: GNI Per Capita ($), Canada, 2006-2011 117
• Table 55: Average Consumer Price Index, Canada, 2005-2010 118
• Table 56: Average Consumer Price Index, Canada, Forecast, 2011-2020 119
• Table 57: Average Consumer Price, Canada, Annual Change (%), 2005-2010 120
• Table 58: Inflation by Commodity, Canada, 2005-2010 121
• Table 59: Currency Exchange Rate (USD/CAD), Canada, 2006-2011 122
• Table 60: Foreign Direct Investment ($bn), Canada, 2006-2011 123
• Table 61: Foreign Exchange Reserves ($bn), Canada, 2006-2011 124
• Table 62: Imports of Goods and Services ($bn), Canada, 2005-2010 125
• Table 63: Exports of Goods and Services ($bn), Canada, 2005-2010 126
• Table 64: General Government Structural Balance ($bn), Canada, 2005-2010 127
• Table 65: General Government Net Debt ($bn), Canada, 2005-2010 128
• Table 66: General Government Net Debt ($bn), Canada, Forecast, 2011-2020 129
• Table 67: Major Goods Producing Industries, Canada, Gross Output ($m), 2010 130
• Table 68: Major Service-Producing Industries, Canada, Gross Output ($m), 2010 131
• Table 69: Population (millions), Canada, 2006-2011 132
• Table 70: Population (millions), Canada, Forecast, 2012-2020 133
• Table 71: Urban and Rural Population, Canada, Share (%), 2005-2010 134
• Table 72: Age Groups, Canada, Population Distribution (%), 2005-2010 135
• Table 73: Age Groups, Canada, Population Distribution (%), Forecast, 2011-2020 136
• Table 74: Births (Per 1000 Population), Canada, 2005-2010 137
• Table 75: Births (per 1000 Population), Canada, Forecast, 2011-2020 138
• Table 76: Mortality (Per 1000 Population), Canada, 2005-2010 139
• Table 77: Major Causes of Mortality ('000), Canada, 2008 140
• Table 78: Children <5 Years Age, Canada, Mortality (Per 1000 Live Births), 2005-2010 141
• Table 79: Immunization Rate for Measles and DPT in Children < 1 Years (%), Canada, 2005-2010 142
• Table 80: Immunization Rate for Influenza in Population > 65 year (%), Canada, 2005-2010 143
• Table 81: Major Causes of Male Mortality ('000), Canada, 2008 144
• Table 82: Major Causes of Female Mortality ('000), Canada, 2008 145
• Table 83: Gender Ratio (M/F), Canada, 2005-2010 146
• Table 84: Life Expectancy at Birth (Years), Canada, 2005-2010 147
• Table 85: Life Expectancy at Birth (Years), Canada, Forecast, 2011-2020 148
• Table 86: Part time and Full-time University Students ('000s), Canada, 2005-2010 149
• Table 87: University Graduation Rate (%), Canada, 2005-2010 150
• Table 88: Unemployment Rate (%), Canada, 2005-2010 151
• Table 89: Major Diseases, Canada, Patients in Residential Care ('000s), 2010-2011 152
• Table 90: Major Diseases, Canada, DALYs (Per 100,000 Population), 2004 153
• Table 91: Hospitals, Canada, 2005-2010 154
• Table 92: Residential Healthcare Facilities by Type of Patients, Canada, 2009 155
• Table 93: Residential Care Facilities by Type of Ownership, Canada, 2009 156
• Table 94: Hospital Beds, Canada, 2005-2010 157
• Table 95: Beds in Residential Healthcare Facilities by Type of Ownership, Canada, 2009 158
• Table 96: Hospital Beds by Type of Care, Canada, 2005-2008 159
• Table 97: CT Scanners (per Million Population), Canada, 2005-2010 160
• Table 98: MRI Machines (per Million Population), Canada, 2005-2010 161
• Table 99: PET Scanners (per Million Population), Canada, 2005-2010 162
• Table 100: Hospital Beds (Per 1000 Population), Canada, 2005-2010 163
• Table 101: Physicians (per 100,000 Population), Canada, 2005-2010 164
• Table 102: General Practitioners (per 100,000 Population), Canada, 2005-2010 165
• Table 103: PM10 (Thousand Tons), Canada, 2005-2010 166
• Table 104: CO2 Emissions (Metric Tons), Canada, 2005-2010 167
• Table 105: Healthcare Workforce (per 100,000 Population), Canada, 2010 168
• Table 106: Healthcare Expenditures (% of GDP), Canada, 2005-2010 169
• Table 107: Healthcare Expenditures, Canada, Share of Major Components (%), 2009 170
• Table 108: Healthcare Expenditures, Canada, Public-Private Share (%), 2005-2010 171
• Table 109: Healthcare Expenditures, Canada, Share of Financing Agents (%), 2009 172
• Table 110: Pharmaceutical R&D Expenditures ($m), Canada, 2005-2010 173
• Table 111: Major Healthcare Trade Fairs, Canada, 2012 175

List of Figures

1.2 List of Figures

• Figure 1: Pharmaceutical Market ($bn), Canada, 2005-2010 13
• Figure 2: Pharmaceutical Market ($bn), Canada, Forecast, 2011-2020 14
• Figure 3: Pharmaceutical Distribution Channel, Canada, 2010 15
• Figure 4: Generic Pharmaceuticals, Canada, Revenue ($bn), 2005-2010 17
• Figure 5: Biologics Pharmaceuticals, Canada, Revenue ($bn), 2005-2010 18
• Figure 6: Biologics Pharmaceuticals, Canada, Revenue ($bn), 2011-2020 19
• Figure 7: OTC Drugs Market, Canada, Revenue ($bn), 2005-2010 20
• Figure 8: Major Disease Areas by Sales of Patented Drug Products, Canada ($bn), 2010 21
• Figure 9: Medical Device Market, Canada, 2006-2011 50
• Figure 10: Medical Device Market, Canada, Forecast, 2012-2020 51
• Figure 11: Medical Device Market, Canada, Segments, Revenue ($m), 2011 52
• Figure 12: Ophthalmic Devices Market ($m), Canada, 2006-2011 53
• Figure 13: Sales Trends for Major Players, Ophthalmic Devices, Canada, 2006-2010 54
• Figure 14: Orthopedic Devices Market ($m), Canada, 2006-2011 55
• Figure 15: Sales Trends for Major Players, Orthopedic Devices, Canada, 2006-2010 56
• Figure 16: Cardiovascular Devices Market ($m), Canada, 2006-2011 57
• Figure 17: Sales Trends for Major Players, Cardiovascular Devices, Canada, 2006-2010 58
• Figure 18: In Vitro Diagnostics Market ($m), Canada, 2006-2011 59
• Figure 19: Sales Trends for Major Players, In Vitro Diagnostics Devices, Canada, 2006-2010 60
• Figure 20: Drug Delivery Devices Market ($m), Canada, 2006-2011 61
• Figure 21: Sales Trends for Major Players, Drug Delivery Devices, Canada, 2006-2010 62
• Figure 22: Major Medical Device Companies, Canada, Revenue ($m), 2010 63
• Figure 23: Drivers and Barriers, Healthcare Market, Canada, 2011 83
• Figure 24: Drug Reimbursement Process, Canada 86
• Figure 25: New Patented Drug Review Process, Canada, 2012 88
• Figure 26: Healthcare Spending, Canada, Patient's Share (%), 2005-2010 91
• Figure 27: Change in Average Price of Patented Drugs (%), Canada, 2005-2010 92
• Figure 28: Health Products and Food Branch, Organization Chart, Canada 93
• Figure 29: New Drug Approval Process, Canada, 2012 96
• Figure 30: New Drug Submission Review Decisions, Canada, 2010 97
• Figure 31: Medical Device Approval Process, Canada, 2012 100
• Figure 32: Patent Approval Process, Canada, 2011 104
• Figure 33: Clinical Trial Regulation Process, Canada, 2011 106
• Figure 34: GDP Per Capita ($), Canada, 2005-2010 113
• Figure 35: GDP Per Capita ($), Canada, Forecast, 2011-2020 114
• Figure 36: GDP, Canada, Annual Growth (%), 2005-2010 115
• Figure 37: GDP, Canada, Annual Growth (%), Forecast, 2011-2020 116
• Figure 38: GNI Per Capita ($), Canada, 2006-2011 117
• Figure 39: Average Consumer Price Index, Canada, 2005-2010 118
• Figure 40: Average Consumer Price Index, Canada, Forecast, 2011-2020 119
• Figure 41: Average Consumer Price, Canada, Annual Change (%), 2005-2010 120
• Figure 42: Inflation by Commodity, Canada, 2005-2010 121
• Figure 43: Currency Exchange Rate (USD/CAD), Canada, 2006-2011 122
• Figure 44: Foreign Direct Investment ($bn), Canada, 2006-2011 123
• Figure 45: Foreign Exchange Reserves ($bn), Canada, 2006-2011 124
• Figure 46: Imports of Goods and Services ($bn), Canada, 2005-2010 125
• Figure 47: Exports of Goods and Services ($bn), Canada, 2005-2010 126
• Figure 48: General Government Structural Balance ($bn), Canada, 2005-2010 127
• Figure 49: General Government Net Debt ($bn), Canada, 2005-2010 128
• Figure 50: General Government Net Debt ($bn), Canada, Forecast, 2011-2020 129
• Figure 51: Major Goods Producing Industries, Canada, Gross Output ($m), 2010 130
• Figure 52: Major Service-Producing Industries, Canada, Gross Output ($m), 2010 131
• Figure 53: Population (millions), Canada, 2006-2011 132
• Figure 54: Population (millions), Canada, Forecast, 2012-2020 133
• Figure 55: Urban and Rural Population, Canada, Share (%), 2005-2010 134
• Figure 56: Age Groups, Canada, Population Distribution (%), 2005-2010 135
• Figure 57: Age Groups, Canada, Population Distribution (%), Forecast, 2011-2020 136
• Figure 58: Births (Per 1000 Population), Canada, 2005-2010 137
• Figure 59: Births (per 1000 Population), Canada, Forecast, 2011-2020 138
• Figure 60: Mortality (Per 1000 Population), Canada, 2005-2010 139
• Figure 61: Major Causes of Mortality ('000s), Canada, 2008 140
• Figure 62: Children <5 Years Age, Canada, Mortality (Per 1000 Live Births), 2005-2010 141
• Figure 63: Immunization Rate for Measles and DPT in Children < 1 years (%), Canada, 2005-2010 142
• Figure 64: Immunization Rate for Influenza in Population > 65 Years (%), Canada, 2005-2010 143
• Figure 65: Major Causes of Male Mortality ('000), Canada, 2008 144
• Figure 66: Major Causes of Female Mortality ('000), Canada, 2008 145
• Figure 67: Gender Ratio (M/F), Canada, 2005-2010 146
• Figure 68: Life Expectancy at Birth (Years), Canada, 2005-2010 147
• Figure 69: Life Expectancy at Birth (Years), Canada, Forecast, 2011-2020 148
• Figure 70: Part-time and Full-time University Students ('000s), Canada, 2005-2010 149
• Figure 71: University Graduation Rate (%), Canada, 2005-2010 150
• Figure 72: Unemployment Rate (%), Canada, 2005-2010 151
• Figure 73: Major Diseases, Canada, Patients in Residential Care ('000s), 2010-2011 152
• Figure 74: Major Diseases, Canada, DALYs (Per 100,000 Population), 2004 153
• Figure 75: Hospitals, Canada, 2005-2010 154
• Figure 76: Residential Healthcare Facilities by Type of Patients, Canada, Share (%), 2009 155
• Figure 77: Residential Care Facilities by Type of Ownership, Canada, 2009 156
• Figure 78: Hospital Beds, Canada, 2005-2010 157
• Figure 79: Beds in Residential Healthcare Facilities by Type of Ownership, Canada, 2009 158
• Figure 80: Hospital Beds by Type of Care, Canada, 2005-2008 159
• Figure 81: CT Scanners (per Million Population), Canada, 2005-2010 160
• Figure 82: MRI Machines (per Million Population), Canada, 2005-2010 161
• Figure 83: PET Scanners (per Million Population), Canada, 2005-2010 162
• Figure 84: Hospital Beds (per 1000 Population), Canada, 2005-2010 163
• Figure 85: Physicians (per 100,000 Population), Canada, 2005-2010 164
• Figure 86: General Practitioners (per 100,000 Population), Canada, 2005-2010 165
• Figure 87: PM10 (Thousand Tons), Canada, 2005-2010 166
• Figure 88: CO2 Emissions (Metric Tons), Canada, 2005-2010 167
• Figure 89: Healthcare Workforce (Per 100,000 Population), Canada, 2010 168
• Figure 90: Healthcare Expenditures (% of GDP), Canada, 2005-2010 169
• Figure 91: Healthcare Expenditures, Canada, Share of Major Components (%), 2009 170
• Figure 92: Healthcare Expenditures, Canada, Public-Private Share (%), 2005-2010 171
• Figure 93: Healthcare Expenditures, Canada, Share of Financing Agents (%), 2009 172
• Figure 94: Pharmaceutical R&D Expenditures ($m), Canada, 2005-2010 173
• Figure 95: Opportunities and Challenges, Healthcare Market, Canada, 2011 177

Healthcare, Regulatory and Reimbursement Landscape - Canada published by GlobalData in September 30, 2012. This report consists of Pages: 187 and the price starts from US $ 1995.

The contents of this page may be different from the latest version. Please contact us for details.